Evolus delivered Q2 revenue of $84.08M, beating consensus by a meaningful margin, with adjusted EBITDA swinging into positive territory. The 21% year-over-year revenue growth reflects sustained momentum in the U.S. toxin market and international expansion. Adjusted EBITDA profitability—a key metric for device and injectables makers—signals that the company's cost structure is now aligned with its revenue base.
Business & M&A
Evolus Q2 Revenue Surges 21%, Adjusted EBITDA Swings Positive
Jeuveau revenue accelerates past forecasts; adjusted EBITDA turns positive as profitability gains traction.
1-YEAR MOVE
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
Adjusted EBITDA swings positive; revenue beats consensus on 21% YoY growth.
The profitability inflection matters for practice economics. A stable, cash-generative Evolus is more likely to invest in market development, rebate programs, and supply chain resilience. For owners on Evolus Rewards or considering Jeuveau as a primary or secondary toxin, this quarter suggests the company has the financial runway to support competitive per-unit pricing and loyalty incentives through 2027.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.